Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a typ…

Early Alzheimer's Disease

~Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT07033494

Phase 2

A Pilot Study to Assess the Effect of Adding 1 Infusion of Human Mesenchymal Stem Cells (hMSC) to Patients Treated With Anti-Amyloid Monoclonal Antibodies Who Are Suffering From Mild Cognitive Impairment or Mild Alzheimer's Disease.

The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal ant…

Mild Cognitive ImpairmentEarly Alzheimer's DiseaseAD-MCI

~Estimated

~$10 – $7,500

Bernard (Barry) BaumelNCT07512362